Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - August 2010 Pharmaceutical Technology Europe - August 2010 Table of Contents The Changing Landscape for Biosimilars Interview with The European Generic Medicines Association The Biosimilars Market Today and Tomorrow A SWOT Analysis of the Biosimilars Market Latest EU Guidelines Dissected Taking On the Regulators: Is It Worth It? Launching and Commercialising Biosimilars Perception, Cost and the Impact on Biotech Innovation Clinical and Cost Considerations of Developing a Biosimilar True Biosimilars Do Not Offer a Compelling Business Case What is Hindering the Uptake of Biosimilars Pharmaceutical Technology Europe - August 2010 Pharmaceutical Technology Europe - August 2010 - Table of Contents (Page 1) Pharmaceutical Technology Europe - August 2010 - The Changing Landscape for Biosimilars (Page 2) Pharmaceutical Technology Europe - August 2010 - Interview with The European Generic Medicines Association (Page 3) Pharmaceutical Technology Europe - August 2010 - Interview with The European Generic Medicines Association (Page 4) Pharmaceutical Technology Europe - August 2010 - Interview with The European Generic Medicines Association (Page 5) Pharmaceutical Technology Europe - August 2010 - The Biosimilars Market Today and Tomorrow (Page 6) Pharmaceutical Technology Europe - August 2010 - A SWOT Analysis of the Biosimilars Market (Page 7) Pharmaceutical Technology Europe - August 2010 - Latest EU Guidelines Dissected (Page 8) Pharmaceutical Technology Europe - August 2010 - Taking On the Regulators: Is It Worth It? (Page 9) Pharmaceutical Technology Europe - August 2010 - Launching and Commercialising Biosimilars (Page 10) Pharmaceutical Technology Europe - August 2010 - Perception, Cost and the Impact on Biotech Innovation (Page 11) Pharmaceutical Technology Europe - August 2010 - Clinical and Cost Considerations of Developing a Biosimilar (Page 12) Pharmaceutical Technology Europe - August 2010 - True Biosimilars Do Not Offer a Compelling Business Case (Page 13) Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars (Page 14) Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars (Page 15) http://www.nxtbookMEDIA.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.